Patents by Inventor Betty Tam

Betty Tam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCER USING A CLK INHIBITOR
    Publication number: 20220062240
    Abstract: Provided herein are methods of treating a cancer in a subject using a CLK inhibitor or pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: June 26, 2019
    Publication date: March 3, 2022
    Inventors: Betty Tam, Carine Bossard, Kevin Tseng Chiu, Heekyung Chung, Luis A. Dellamary, Chi Ching Mak, Long Hoang Do, Seong Yeon Cho, Luke Jervis
  • 150 KDA TGF-B1 accessory receptor acts a negative modulator of TGF-B signaling
    Patent number: 7173002
    Abstract: The present invention relates to a TGF-?1 binding protein called r150. This protein has a GPI-anchor contained in r150 itself and not on a tightly associated protein and that it binds TGF-?1 with an affinity comparable to those of the signaling receptors. Furthermore, the released (soluble) form of this protein binds TGF-?1 independent of the types I and II receptors. Also, the soluble form inhibits the binding of TGF-? to its receptor. In addition, evidence that r150 is released from the cell surface by an endogenous phospholipase C is provided. Also, the creation of a mutant human keratinocyte cell line with a defect in GPI synthesis which displays reduced expression of r150 is described. Our results using these mutant keratinocytes suggest that the membrane anchored form of r150 is a negative modulator of TGF-beta responses.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: February 6, 2007
    Assignee: McGill University
    Inventors: Anie Philip, Betty Tam
  • 150 Kda accessory receptor for tgf-beta
    Publication number: 20040191860
    Abstract: The present invention relates to a TGF-&bgr;1 binding protein called r150. This protein has a GPI-anchor contained in r150 itself and not on a tightly associated protein and that it binds TGF-&bgr;1 with an affinity comparable to those of the signaling receptors. Furthermore, the released (soluble) form of this protein binds TGF-&bgr;1 independent of the types I and II receptors. Also, the soluble form inhibits the binding of TGF-&bgr; to its receptor. In addition, evidence that r150 is released from the cell surface by an endogenous phospholipase C is provided. Also, the creation of a mutant human keratinocyte cell line with a defect in GPI synthesis which displays reduced expression of r150 is described. Our results using these mutant keratinocytes suggest that the membrane anchored form of r150 is a negative modulator of TGF-beta responses.
    Type: Application
    Filed: May 13, 2004
    Publication date: September 30, 2004
    Inventors: Anie Philip, Betty Tam